In this interview we discuss results of the PlanB trial, which showed that use of the 21-gene recurrence score, Oncotype DX, can identify patients with early breast cancer who likely do not need chemotherapy.
Oleg Gluz, MD
Advertisement
Articles by Oleg Gluz, MD
Advertisement
Latest Updated Articles
Multigene Testing to Forgo Chemotherapy in Early Breast CancerPublished: April 25th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
3
Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC
4
Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma
5
